Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL

详细信息    查看全文

• 作者：Martin Dichgans ; Hugh S Markus ; Stephen Salloway ; Auli Verkkoniemi ; Margaret Moline ; Qin Wang ; Holly Posner ; Hugues S Chabriat
• 关键词：Nanomaterials ; Perovskites ; Calcium strontium titanate ; Crystallinity ; Hydroxyl defect
• 刊名：Lancet Neurology
• 出版年：2008
• 出版时间：April 2008
• 年：2008
• 卷：7
• 期：4
• 页码：310-318
• 全文大小：180 K

文摘

Cholinergic deficits might contribute to vascular cognitive impairment. Trials of cholinesterase inhibitors in patients with vascular dementia are difficult because of heterogeneous disease mechanisms and overlap between vascular and Alzheimer's disease (AD) pathology in the age-group recruited. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is a genetic form of subcortical ischaemic vascular dementia. It represents a homogeneous disease process, and because of CADASIL's early onset, comorbid AD pathology is rare. We did a multicentre, 18-week, placebo-controlled, double-blind, randomised parallel-group trial to determine whether the cholinesterase inhibitor donepezil improves cognition in patients with CADASIL.